Measurement of activity of urea resistant neutrophil alkaline phosphatase as an antenatal screening test for Down's syndrome

OBJECTIVE--To investigate the value of measuring maternal urea resistant neutrophil alkaline phosphatase activity as an antenatal screening test for Down's syndrome. DESIGN--Case-control study of blood samples collected at nine to 27 weeks of pregnancy. SETTING--Antenatal clinics in London and...

Full description

Saved in:
Bibliographic Details
Published inBMJ Vol. 301; no. 6759; pp. 1024 - 1026
Main Authors Cuckle, H S, Wald, N J, Goodburn, S F, Sneddon, J, Amess, J A, Dunn, S C
Format Journal Article
LanguageEnglish
Published London British Medical Journal Publishing Group 03.11.1990
British Medical Association
BMJ Publishing Group LTD
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:OBJECTIVE--To investigate the value of measuring maternal urea resistant neutrophil alkaline phosphatase activity as an antenatal screening test for Down's syndrome. DESIGN--Case-control study of blood samples collected at nine to 27 weeks of pregnancy. SETTING--Antenatal clinics in London and Oxford. PATIENTS--72 Women whose fetuses had been diagnosed by amniocentesis or chorionic villus sampling as having Down's syndrome and 156 women whose fetuses did not have the syndrome. Only singleton pregnancies were studied. MAIN OUTCOME MEASURE--Activity of urea resistant neutrophil alkaline phosphatase measured cytochemically. RESULTS--The median enzyme activity in the index patients was 1.65 times the expected median for the controls at the same duration of pregnancy (p less than 0.0001; 95% confidence interval 1.56 to 1.74). A cut off value that identified the 5% of control patients with the highest activities yielded a rate of detection of Down's syndrome of 79% (95% confidence interval 70 to 89%). CONCLUSION--Activity of urea resistant neutrophil alkaline phosphatase is an effective maternal blood marker for Down's syndrome. Its use in antenatal screening could lead to a substantial improvement in the detection of this disorder. Before introducing the test into routine medical practice it will have to be automated so that it can be used on a large scale and is less subjective.
Bibliography:href:bmj-301-1024.pdf
ark:/67375/NVC-ZK8VMLN5-Q
local:bmj;301/6759/1024
istex:ACE8065F461C3A4A796ABEF249A2DBFCEE196B57
PMID:2147397
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0959-8138
0959-8146
1468-5833
1756-1833
DOI:10.1136/bmj.301.6759.1024